1-(4-methoxyphenyl)-2-(2-thienyl)ethene | 99698-09-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-methoxyphenyl)-2-(2-thienyl)ethene
• 英文别名: 2-[2-(4-Methoxyphenyl)ethenyl]thiophene
• CAS: 99698-09-6
• 化学式: C₁₃H₁₂OS
• 分子量: 216.304
• InChiKey: KYPWMKCTXUVDQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-methoxyphenyl)-2-(2-thienyl)ethene 在 乙酸酐 、 三乙胺 、 三氯氧磷 作用下， 反应 7.0h， 生成 E-3-<5-(4-methoxyphenylethenyl)-2-thienyl>-2-phenylacrylic acid
  参考文献：
  名称：

  Karminski-Zamola, Grace; Bajic, Miro, Heterocycles, 1985, vol. 23, # 6, p. 1497 - 1501

  摘要：

  DOI：
• 作为产物：
  描述：

  E-3-(2-thienyl)-2-(4-methoxyphenyl)acrylic acid 在 喹啉 、 铜 作用下， 反应 3.0h， 以34.7%的产率得到1-(4-methoxyphenyl)-2-(2-thienyl)ethene
  参考文献：
  名称：

  Karminski-Zamola, Grace; Bajic, Miro, Heterocycles, 1985, vol. 23, # 6, p. 1497 - 1501

  摘要：

  DOI：

文献信息

• ALPHA-SYNUCLEIN LIGANDS
  申请人：Washington University

  公开号：US20170189566A1

  公开（公告）日：2017-07-06

  The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).

  本发明通常涉及作为α-突触核蛋白配体有用的各种化合物。该发明进一步涉及使用这些化合物及其放射标记类似物用于检测突触核蛋白病，包括帕金森病（PD）的方法。
• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• New Uncharged 2-Thienostilbene Oximes as Reactivators of Organophosphate-Inhibited Cholinesterases
  作者：Milena Mlakić、Tena Čadež、Danijela Barić、Ivana Puček、Ana Ratković、Željko Marinić、Kornelija Lasić、Zrinka Kovarik、Irena Škorić

  DOI：10.3390/ph14111147

  日期：——

  comprises an antimuscarinic drug and an oxime reactivator of the inhibited enzyme. Oximes in use have quaternary nitrogens, and therefore poorly cross the brain–blood barrier. In this work, we synthesized novel uncharged thienostilbene oximes by the Wittig reaction, converted to aldehydes by Vilsmeier formylation, and transformed to the corresponding uncharged oximes in very high yields. Eight trans,anti-

  作为神经毒剂和杀虫剂的有机磷 (OP) 对乙酰胆碱酯酶 (AChE) 和丁酰胆碱酯酶 (BChE) 的抑制会损害外周和中枢神经系统 (CNS) 中的正常胆碱能神经信号转导，从而导致胆碱能危象。治疗包括抗毒蕈碱药物和被抑制酶的肟再活化剂。使用中的肟含有季氮，因此很难穿过脑血屏障。在这项工作中，我们通过 Wittig 反应合成了新型不带电荷的噻吩并芪肟，通过 Vilsmeier 甲酰化转化为醛，并以非常高的产率转化为相应的不带电荷的肟。八反、反和反、同肟的异构体作为神经毒剂抑制的 AChE 和 BChE 的再活化剂进行了测试。四种衍生物在两小时内重新激活环沙林抑制的 BChE 高达 70%，对接研究证实了它们与环沙林抑制的 BChE 活性位点的有效相互作用。基于 AChE 和 BChE 对所有选定肟的中等结合亲和力，并在计算机上评估了 ADME 在亲脂性和 CNS 活性方面​​的特性，这些化合物呈现出一类新的肟，具有进一步开发
• SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
  申请人：STC. UNM

  公开号：US20130178536A1

  公开（公告）日：2013-07-11

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.
• THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS
  申请人：STC. UNM

  公开号：US20160287531A1

  公开（公告）日：2016-10-06

  The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.